Share on LinkedInShare on LinkedIn

ARTICLE · 14 JULY 2014

Federal Court Considers PMPRB Jurisdiction Over Generic Manufacturers

Torys
Torys
Contributor
Torys

Torys

Torys LLP is an international business law firm that works with clients who expect the best advice...

View firm profile
Explore more from Torys

The Federal Court released two related decisions dealing with the jurisdiction of the Patented Medicine Prices Review Board over generic drugs.

CanadaIntellectual Property

On May 27, 2014, the Federal Court released two related decisions, Sandoz Canada Inc. v. Canada (Sandoz) and Ratiopharm Inc. (now Teva Canada Limited) v. Canada (Ratiopharm) dealing with the jurisdiction of the Patented Medicine Prices Review Board (PMPRB) over generic drugs and, arguably, any genericized drug.

Under section 2 of the Patent Act (Act), a patentee is a person entitled to the benefit of a patent. Similarly, a "patentee" under section 79(1), in respect of an invention pertaining to a medicine, "includes, where any other person is entitled to exercise any rights in relation to that patent . . . that other person in respect of those rights." The PMPRB decided in each of the two decisions that its jurisdiction extended to generic manufacturers. Each of Sandoz and Ratiopharm appealed the Board's decision to the Federal Court.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from